ChromaDex (NASDAQ:CDXC) Given New $11.00 Price Target at HC Wainwright

ChromaDex (NASDAQ:CDXC) had its price target lifted by investment analysts at HC Wainwright from $8.00 to $11.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 39.24% from the company’s current price.

Other analysts have also recently issued research reports about the stock. LADENBURG THALM/SH SH raised their target price on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 6th.

ChromaDex Stock Performance

NASDAQ CDXC opened at $7.90 on Monday. The firm has a 50-day moving average of $5.87 and a 200-day moving average of $5.27. The stock has a market cap of $614.23 million, a PE ratio of 790.79 and a beta of 2.21. ChromaDex has a 52-week low of $1.77 and a 52-week high of $9.18.

Insider Buying and Selling at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now directly owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

Several hedge funds and other institutional investors have recently made changes to their positions in CDXC. D. E. Shaw & Co. Inc. grew its holdings in shares of ChromaDex by 1,785.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock valued at $5,365,000 after purchasing an additional 957,665 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of ChromaDex by 288.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock valued at $3,517,000 after purchasing an additional 492,148 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of ChromaDex by 189.0% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 506,186 shares of the company’s stock valued at $2,685,000 after purchasing an additional 331,014 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of ChromaDex during the 4th quarter valued at approximately $1,647,000. Finally, Renaissance Technologies LLC grew its holdings in shares of ChromaDex by 68.0% during the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after purchasing an additional 288,588 shares during the last quarter. 15.41% of the stock is owned by institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.